MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026

MetaVia posts strong Phase 1 data for DA-1726, but value inflection is years away.

What the company is saying

MetaVia Inc. is highlighting the acceptance of its DA-1726 abstract for poster presentation at ObesityWeek 2026, emphasizing the drug's novel dual GLP1R/GCGR agonist mechanism and its potential in treating MetALD and ALD. The company stresses the scientific credibility of DA-1726 by disclosing a 13.5% placebo-adjusted reduction in body weight and a 68% placebo-adjusted reduction in liver fat in a Phase 1 Part 3B interim analysis at Day 109. The narrative frames DA-1726 as having a distinct metabolic profile and comparable weight loss to Retatrutide, though no direct comparative data are included in the release. MetaVia also outlines its pipeline, including vanoglipel (DA-1241) in combination with resmetirom for MASH, with a Phase 2a proof-of-concept study targeted for the first half of 2027. The announcement is positioned as a scientific and clinical progress update, with a confident tone and a focus on future milestones. No financial, revenue, or partnership details are provided, and the company does not address funding or operational risks in this communication.

What the data suggests

The disclosed figures show that DA-1726 achieved a 13.5% placebo-adjusted reduction in body weight and a 68% placebo-adjusted reduction in liver fat at Day 109 of a Phase 1 Part 3B interim analysis. These results are accompanied by reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass, suggesting a favorable efficacy and safety profile at this early stage. The company provides clear timelines for its next steps: a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD is targeted to begin in the second half of 2027, and a Phase 2a proof-of-concept study of vanoglipel with resmetirom for MASH is planned for the first half of 2027. The release does not present any financial data, cash position, or funding status, so the company's ability to finance these long-term studies cannot be assessed from this announcement. The claim of comparability to Retatrutide is made in the poster title, but no direct comparative data are disclosed. Overall, the data support the scientific rationale for DA-1726, but all value-driving clinical milestones remain at least 18 months away.

Analysis

The announcement is upbeat, highlighting the acceptance of a scientific abstract and reporting promising Phase 1 interim results for DA-1726, including specific numerical reductions in body weight and liver fat. However, the majority of the forward-looking claims relate to planned Phase 2 and Phase 2a studies that will not begin until 2027, meaning any clinical or commercial benefits are at least 1.5 years away. The release does not disclose any financial, revenue, or funding data, nor does it mention capital outlays or commercial partnerships, so capital intensity cannot be assessed. The tone is somewhat inflated by referencing a comparison to Retatrutide in the poster title, but no direct comparative data are disclosed. Overall, the narrative is more optimistic than the current stage of development justifies, but the presence of specific Phase 1 efficacy data grounds the announcement in real progress.

Risk flags

• ●The primary risk is executional: both the Phase 2 study for DA-1726 and the Phase 2a study for vanoglipel are not scheduled to begin until 2027, so any clinical or commercial value realization is long-dated and subject to delays or setbacks in trial initiation and enrollment.
• ●There is no disclosure of financial position, cash runway, or funding for the planned trials, making it impossible to assess whether MetaVia has the resources to reach these long-term milestones. This creates uncertainty about the company's ability to sustain operations through to value inflection points.
• ●The claim of comparable weight loss to Retatrutide is made in the poster title, but the release provides no head-to-head data or statistical comparisons, increasing the risk that investor expectations are set by unsubstantiated comparisons rather than hard evidence.

Bottom line

MetaVia's announcement provides clear and promising Phase 1 efficacy data for DA-1726, with a 13.5% placebo-adjusted reduction in body weight and a 68% reduction in liver fat, but all major clinical milestones are at least 18 months away. The company is positioning DA-1726 as a differentiated asset in the cardiometabolic space, but the only claim of comparability to Retatrutide is in the poster title, not in disclosed data. No financial or funding information is provided, so investors cannot gauge the company's ability to finance its long-term pipeline. The absence of near-term catalysts and the long runway to Phase 2 trial initiation mean that this update is primarily of scientific interest, not immediate commercial significance. The most important takeaway is that while early data are strong, the timeline to any value realization is long and dependent on successful execution and future funding. Investors should expect a period of limited news flow until at least mid-2027.

Announcement summary

(NASDAQ:MTVA) MetaVia Inc. announced that an abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for a poster presentation at ObesityWeek 2026, scheduled for November 14-17, 2026. The poster, titled 'DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide,' will be presented by Il Hoon Jeong, MS, Research Scientist, Dong-A ST Research Center, as Poster-229 in the 'Gut Peptides, Appetite Signaling & Novel Therapeutics' session on November 14, 2026, from 7:30-8:30 pm ET in Exhibit Hall BCD. DA-1726 is being developed for once-weekly, subcutaneous administration to address various cardiometabolic indications, including Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD). DA-1726 is engineered with a 3:1 GLP1R:GCGR potency ratio to balance appetite and glucose control with energy expenditure and fat breakdown. Preclinical tissue-distribution studies have shown DA-1726 concentrates most heavily in adipose tissue and the liver. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated a 13.5% placebo-adjusted reduction in body weight and a 68% placebo-adjusted reduction in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. MetaVia is planning a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027. MetaVia is also advancing vanoglipel (DA-1241), a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119), in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to glucose lowering effects. A Phase 2a proof-of-concept study of vanoglipel in combination with resmetirom for MASH is targeted to begin in the first half of 2027.

Disagree with this article?